PCM
ZYME icon

Penserra Capital Management’s Zymeworks ZYME Stock Holding History

Penserra Capital Management’s Portfolio ZYME Stock Details ZYME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-60,146
Closed -$1.58M – 1198
2025
Q4 		$1.58M Buy
+60,146
New +$1.31M 0.02% 351

Other funds holding ZYME

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Penserra Capital Management's ZYME Position: Q1 2026 in Review

Penserra Capital Management sold out of Zymeworks (ZYME) in Q1 2026, closing a stake of 60,146 shares — an estimated $1.58M sold.

Penserra Capital Management first reported a position in ZYME in Q4 2025 and held it in 1 quarter. The position peaked at $1.58M in Q4 2025. 211 funds tracked by Wall St. Rank hold ZYME as of Q1 2026.

  • Penserra Capital Management reported no remaining Zymeworks position as of Q1 2026 after selling out during the quarter.
  • Penserra Capital Management sold 60,146 Zymeworks shares in Q1 2026, an estimated $1.58M.
  • Penserra Capital Management first reported a position in Zymeworks in Q4 2025 and held it in 1 quarter.
  • Penserra Capital Management's Zymeworks position peaked at $1.58M in Q4 2025.
  • 211 funds tracked by Wall St. Rank held Zymeworks as of Q1 2026.

Based on Penserra Capital Management's 13F filing for Q1 2026, filed 11 May 2026.